Test Id : ALUPP
Lupus Anticoagulant Profile, Plasma
Useful For
Suggests clinical disorders or settings where the test may be helpful
Confirming or excluding the presence of lupus anticoagulant (LA), distinguishing LA from specific coagulation factor inhibitors and nonspecific inhibitors
Investigating a prolonged activated thromboplastin time, especially when combined with other coagulation studies
This test is not useful for the detection of antiphospholipid antibodies that do not affect coagulation tests. We recommend separate testing for serum phospholipid (cardiolipin), IgG and IgM (CLPMG) and beta-2 glycoprotein 1, IgG and IgM (B2GMG).
Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
ALUPI | Lupus Anticoagulant Tech Interp | No | Yes |
PTSC | Prothrombin Time (PT), P | Yes, (order PTTP) | Yes |
APTSC | Activated Partial Thrombopl Time, P | Yes, (order APTTP) | Yes |
DRV1 | Dilute Russells Viper Venom Time, P | Yes, (order DRVI1) | Yes |
Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
DIMER | D-Dimer, P | Yes, (order DDITT) | No |
F8IS | Coag Factor VIII Assay Inhib Scrn,P | No | No |
FACTV | Coag Factor V Assay, P | Yes | No |
F_7 | Coag Factor VII Assay, P | Yes | No |
TTSC | Thrombin Time (Bovine), P | Yes | No |
F_9 | Coag Factor IX Assay, P | Yes | No |
F_10 | Coag Factor X Assay, P | Yes | No |
F_11 | Coag Factor XI Assay, P | Yes | No |
F_12 | Coag Factor XII Assay, P | Yes | No |
F8A | Coag Factor VIII Activity Assay, P | Yes | No |
RTSC | Reptilase Time, P | Yes | No |
F_2 | Coag Factor II Assay, P | Yes | No |
CLFIB | Fibrinogen, Clauss, P | Yes, (order FIBTP) | No |
SOLFM | Soluble Fibrin Monomer | No | No |
PNP | Platelet Neutralization Procedure | No | No |
PTMSC | PT Mix 1:1 | No | No |
APMSC | APTT Mix 1:1 | No | No |
DRV2 | DRVVT Mix | No | No |
DRV3 | DRVVT Confirmation | No | No |
ALUPO | Lupus Anticoagulant Interp | No | No |
RIST | Ristocetin Cofactor, P | No | No |
F5_IS | Factor V Inhib Scrn | No | No |
VWFMP | von Willebrand Factor Multimer, P | Yes, ( order VWFMS ) | No |
VWAG | von Willebrand Factor Ag, P | Yes | No |
VWACT | von Willebrand Factor Activity, P | Yes | No |
CH9 | Chromogenic FIX, P | Yes | No |
5BETH | FV Bethesda Units, P | No | No |
F9_IS | Factor IX Inhib Scrn | No | No |
8BETH | FVIII Bethesda Units, P | No | No |
9BETH | FIX Bethesda Units, P | No | No |
CHF8 | Chromogenic FVIII, P | Yes | No |
HEXLA | HEX LA, P | No | No |
PTFIB | PT-Fibrinogen, P | No | No |
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Initial testing includes prothrombin time (PT), activated partial thromboplastin time (aPTT), and dilute Russell's viper venom time (dRVVT).
If the PT, aPTT, and dRVVT are normal, a computer-generated interpretive comment indicating no evidence of a lupus anticoagulant (LA) will be provided.
If PT is greater than 13.9 seconds, PT mix will be performed at an additional charge.
If aPTT is greater than or equal to 38 seconds, aPTT mix will be performed at an additional charge.
If PT, aPTT, or dRVVT are prolonged, thrombin time (TT) will be performed at an additional charge.
If aPTT mix is greater than or equal to 38 seconds and thrombin time is less than 35.0 seconds (no evidence of heparin), platelet neutralization procedure will be performed at an additional charge.
If dRVVT ratio is greater than or equal to 1.20, dRVVT mix and dRVVT confirmation will be performed at an additional charge.
If TT is greater than or equal to 25.0 seconds, reptilase will be performed at an additional charge.
If appropriate, coagulation factor assays, fibrinogen, D-dimer, hexagonal LA, and soluble fibrin monomer will be performed, at an additional charge, to clarify a significant abnormality in the screen test results.
If the factor VIII, IX or V result is below the normal range, the factor inhibitor screen may be performed along with the Bethesda titering assay, if indicated, at an additional charge.
If any test results are abnormal, all results will be reviewed by a coagulation consultant and a lupus anticoagulant interpretation will be provided.
For more information see Lupus Anticoagulant Profile Testing Algorithm.
Method Name
A short description of the method used to perform the test
ALUPI: Technical Interpretation
PTSC, APTSC, DRV1: Optical Clot-Based
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
APTT Mixing Studies
Coag
Dilute Russell Viper Venom Time (DRVVT)
DRVVT (Dilute Russell Viper Venom Time)
Platelet Neutralization Procedure (PNP Coag Consult)
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Initial testing includes prothrombin time (PT), activated partial thromboplastin time (aPTT), and dilute Russell's viper venom time (dRVVT).
If the PT, aPTT, and dRVVT are normal, a computer-generated interpretive comment indicating no evidence of a lupus anticoagulant (LA) will be provided.
If PT is greater than 13.9 seconds, PT mix will be performed at an additional charge.
If aPTT is greater than or equal to 38 seconds, aPTT mix will be performed at an additional charge.
If PT, aPTT, or dRVVT are prolonged, thrombin time (TT) will be performed at an additional charge.
If aPTT mix is greater than or equal to 38 seconds and thrombin time is less than 35.0 seconds (no evidence of heparin), platelet neutralization procedure will be performed at an additional charge.
If dRVVT ratio is greater than or equal to 1.20, dRVVT mix and dRVVT confirmation will be performed at an additional charge.
If TT is greater than or equal to 25.0 seconds, reptilase will be performed at an additional charge.
If appropriate, coagulation factor assays, fibrinogen, D-dimer, hexagonal LA, and soluble fibrin monomer will be performed, at an additional charge, to clarify a significant abnormality in the screen test results.
If the factor VIII, IX or V result is below the normal range, the factor inhibitor screen may be performed along with the Bethesda titering assay, if indicated, at an additional charge.
If any test results are abnormal, all results will be reviewed by a coagulation consultant and a lupus anticoagulant interpretation will be provided.
For more information see Lupus Anticoagulant Profile Testing Algorithm.
Specimen Type
Describes the specimen type validated for testing
Plasma Na Cit
Ordering Guidance
Multiple coagulation profile tests are available. See Coagulation Profile Comparison for testing that is performed with each profile.
Shipping Instructions
Send the aliquots in the same shipping container.
Necessary Information
Note if patient is currently receiving anticoagulant (eg, heparin, Coumadin [warfarin]) treatment.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Patient Preparation:
1. If possible, patient should not be receiving anticoagulant treatment (eg, warfarin, heparin): If not possible for medical reasons, note on request.
a. If medically feasible, for 4 to 6 hours before specimen collection, do not administer intravenous heparin.
b. If medically feasible, for 10 to 14 days before specimen collection, do not administer subcutaneous heparin or Coumadin (warfarin).
2. Patient should not be receiving fibrinolytic agents (streptokinase, urokinase, tissue plasminogen activator: tPA).
3. If patient has been recently transfused, it is best to perform this study pretransfusion, if possible.
Specimen Type: Platelet-poor plasma
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Light-blue top (citrate)
Submission Container/Tube: Plastic vials
Specimen Volume: 4 mL in 4 plastic vials each containing 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma (1-2 mL per aliquot) into 4 separate plastic vials, leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, -40 degrees C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Special Instructions
Library of PDFs including pertinent information and forms related to the test
Forms
1. Coagulation Patient Information (T675)
2. If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
3 mL in 3 plastic vials each containing 1 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Confirming or excluding the presence of lupus anticoagulant (LA), distinguishing LA from specific coagulation factor inhibitors and nonspecific inhibitors
Investigating a prolonged activated thromboplastin time, especially when combined with other coagulation studies
This test is not useful for the detection of antiphospholipid antibodies that do not affect coagulation tests. We recommend separate testing for serum phospholipid (cardiolipin), IgG and IgM (CLPMG) and beta-2 glycoprotein 1, IgG and IgM (B2GMG).
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Initial testing includes prothrombin time (PT), activated partial thromboplastin time (aPTT), and dilute Russell's viper venom time (dRVVT).
If the PT, aPTT, and dRVVT are normal, a computer-generated interpretive comment indicating no evidence of a lupus anticoagulant (LA) will be provided.
If PT is greater than 13.9 seconds, PT mix will be performed at an additional charge.
If aPTT is greater than or equal to 38 seconds, aPTT mix will be performed at an additional charge.
If PT, aPTT, or dRVVT are prolonged, thrombin time (TT) will be performed at an additional charge.
If aPTT mix is greater than or equal to 38 seconds and thrombin time is less than 35.0 seconds (no evidence of heparin), platelet neutralization procedure will be performed at an additional charge.
If dRVVT ratio is greater than or equal to 1.20, dRVVT mix and dRVVT confirmation will be performed at an additional charge.
If TT is greater than or equal to 25.0 seconds, reptilase will be performed at an additional charge.
If appropriate, coagulation factor assays, fibrinogen, D-dimer, hexagonal LA, and soluble fibrin monomer will be performed, at an additional charge, to clarify a significant abnormality in the screen test results.
If the factor VIII, IX or V result is below the normal range, the factor inhibitor screen may be performed along with the Bethesda titering assay, if indicated, at an additional charge.
If any test results are abnormal, all results will be reviewed by a coagulation consultant and a lupus anticoagulant interpretation will be provided.
For more information see Lupus Anticoagulant Profile Testing Algorithm.
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Lupus anticoagulant (LA) is an antibody to negatively charged phospholipid that interferes with phospholipid-dependent coagulation tests.
LA is found in, but not limited to, patients with systemic lupus erythematosus; LA is associated with other autoimmune disorders and collagen vascular disease and occurs in response to medications or certain infections (eg, respiratory tract infections in children) and in individuals with no obvious underlying disease.
Lupus anticoagulant has been associated with arterial and venous thrombosis and fetal loss. Individuals with thrombocytopenia or factor II deficiency associated with LA may be at risk for bleeding.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
An interpretive report will be provided.
Interpretation
Provides information to assist in interpretation of the test results
An interpretive report will be provided when testing is complete.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Treatment with heparin causes false-positive results of in vitro coagulation testing for lupus anticoagulant.
Coumadin (warfarin) treatment may impair ability to detect the more subtle varieties of lupus-like anticoagulants.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost. 2003;1(5):931-942
2. Levin JS, Branch DW, Rauch J. The antiphospholipid syndrome. New Engl J Med. 2002;346(10):752-763
3. Proven A, Bartlett RP, Moder KG et al. Clinical importance of positive tests for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc. 2004;79(4):467-475
4. Kitches CS, Kessler CM, Konkle BA, et al. Consultative Hemostasis and Thrombosis. 4th ed. Elsevier; 2019:374-395
Method Description
Describes how the test is performed and provides a method-specific reference
Prothrombin Time:
The prothrombin time (PT) assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is incubated and combined with a PT reagent containing recombinant human tissue factor, synthetic phospholipids, calcium chloride, polybrene, and buffer. The tissue thromboplastin-factor VII/VIIa complex activates factor X. Activated factor X (factor Xa) forms a complex with factor Va, calcium, and phospholipid to activate factor II (prothrombin) to thrombin. Thrombin then acts on fibrinogen (factor I) to form fibrin which clots, the time to clot formation is measured optically using a wavelength of 671 nm providing the assay endpoint (the "prothrombin time").(Package insert: HemosIL RecombiPlasTin 2G. Instrumentation Laboratory Company; R0, 03/2019)
Activated Partial Thromboplastin Time:
The activated partial thromboplastin time (aPTT) assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is combined and incubated with an aPTT reagent containing phospholipid, a negatively charged contact factor activator, and buffer. After a specified incubation time, calcium is added to trigger the coagulation process in the mixture. Subsequently, the time to clot formation is measured optically using a wavelength of 671 nm. Mixing studies (see APMSC / Activated Partial Thromboplastin Time (APTT) Mix 1:1, Plasma) using normal pooled plasma are performed in the Special Coagulation Laboratory on samples with a prolonged aPTT, to assist in discriminating between factor deficiency states and coagulation inhibitors, unless further testing is not indicated.(Package insert: HemosIL SynthASil. Instrumentation Laboratory Company; R11, 06/2017)
Dilute Russell's Viper Venom Time:
The dilute Russell's viper venom time (dRVVT) screening assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is incubated for a specified time, and then combined with a dRVVT screening reagent containing Russell's viper venom, phospholipids, heparin neutralizing agents, calcium, buffers and stabilizers to trigger the coagulation process. Subsequently, the time to clot formation is measured optically using a wavelength of 671 nm. The patient dRVVT screening clotting time is normalized by dividing the patient result by the mean DRVVT screening clotting time of normal pooled plasma to yield a ratio (dRVVT screen ratio).(Package insert: LA CHECK DRVVT. Precision Biologic; R14, 03/2012)
Technical Interpretation:
If the prothrombin time, activated partial thromboplastin time, and dilute Russell viper venom time are normal, a computer-generated interpretive comment will be provided indicating no evidence of a lupus anticoagulant.
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
See Individual Test IDs
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
85610
85730
85613
85390
85130 (if appropriate)
85130 (if appropriate)
85210 (if appropriate)
85220 (if appropriate)
85230 (if appropriate)
85240 (if appropriate)
85245 (if appropriate)
85246 (if appropriate)
85247 (if appropriate)
85250 (if appropriate)
85260 (if appropriate)
85270 (if appropriate)
85280 (if appropriate)
85335 (if appropriate)
85335 (if appropriate)
85335 (if appropriate)
85366 (if appropriate)
85379 (if appropriate)
85384 (if appropriate)
85385 (if appropriate)
85390-26 (if appropriate)
85397 (if appropriate)
85597 (if appropriate)
85598 (if appropriate)
85611 (if appropriate)
85613 (if appropriate)
85613 (if appropriate)
85635 (if appropriate)
85670 (if appropriate)
85732 (if appropriate)
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
ALUPP | Lupus Anticoagulant Prof | 75881-3 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
APTSC | Activated Partial Thrombopl Time, P | 14979-9 |
ALUPI | Lupus Anticoagulant Tech Interp | 75882-1 |
INRSC | INR | 6301-6 |
PTSEC | Prothrombin Time (PT), P | 5902-2 |
RVR1 | DRVVT Screen Ratio | 15359-3 |
Test Setup Resources
Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.
Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.
SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.
Test Update Resources
Change Type | Effective Date |
---|---|
File Definition - Result ID | 2023-11-29 |